Major adverse cardiovascular events in Survivors of Immune-mediated Thrombotic Thrombocytopenic Purpura.
Sign Up to like & getrecommendations! Published in 2021 at "American journal of hematology"
DOI: 10.1002/ajh.26341
Abstract: Cardiovascular disease is a leading cause of death in survivors of immune-mediated thrombotic thrombocytopenic purpura (iTTP), but the epidemiology of major adverse cardiovascular events (MACE) in iTTP survivors is unknown. We evaluated the prevalence and… read more here.
Keywords: survivors immune; thrombotic thrombocytopenic; immune mediated; major adverse ... See more keywords
Preemptive cyclosporin A in immune‐mediated thrombotic thrombocytopenic purpura
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13886
Abstract: Survivors of immune‐mediated thrombotic thrombocytopenic purpura (iTTP) are exposed to clinical relapses when a disintegrin and metalloproteinase with thrombospondin type 1 repeats, member 13 (ADAMTS13) activity decreases during follow‐up. Although preemptive rituximab usually improves ADAMTS13… read more here.
Keywords: mediated thrombotic; immune mediated; activity; thrombotic thrombocytopenic ... See more keywords
Complement-Mediated Thrombotic Microangiopathy and Spontaneous Splenic Rupture Associated With Cytomegalovirus Infection
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Investigative Medicine High Impact Case Reports"
DOI: 10.1177/23247096231172467
Abstract: This is a case report of a previously healthy female patient with complement-mediated thrombotic microangiopathy (TMA) caused by a systemic cytomegalovirus infection that was successfully treated with plasmapheresis, steroids, and parenteral valganciclovir. Complement-mediated TMA is… read more here.
Keywords: thrombotic microangiopathy; mediated thrombotic; complement; cytomegalovirus infection ... See more keywords
Complement-mediated thrombotic microangiopathy associated with lupus nephritis.
Sign Up to like & getrecommendations! Published in 2018 at "Blood advances"
DOI: 10.1182/bloodadvances.2018019596
Abstract: Complement-mediated thrombotic microangiopathy (CM-TMA) is a clinical disorder driven by the generation of excess complement. It is characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) with microvascular thrombosis resulting in systemic organ damage (TMA). One… read more here.
Keywords: complement; lupus nephritis; thrombotic microangiopathy; mediated thrombotic ... See more keywords
More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022009021
Abstract: : Conflict of interest: COI declared - see note COI notes: Y.B. is a member of the French advisory boards for Sanofi and Takeda. A.V. is a member of the French advisory boards for Sanofi,… read more here.
Keywords: frontline caplacizumab; mediated thrombotic; immune mediated; caplacizumab immune ... See more keywords